-0.15%
-0.38%
-9.54%
-25.13%
40.29%
164.53%
198.64%
AI Spotlight on KRYS
Company Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome.
Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product.Krystal Biotech, Inc.was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Market Data
| Last Price | 156.07 |
| Change Percentage | -0.15% |
| Open | 158.59 |
| Previous Close | 156.3 |
| Market Cap ( Millions) | 4489 |
| Volume | 145131 |
| Year High | 219.34 |
| Year Low | 107.5 |
| M A 50 | 168.04 |
| M A 200 | 177.14 |
Financial Ratios
| FCF Yield | 1.29% |
| Dividend Yield | 0.00% |
| ROE | 6.34% |
| Debt / Equity | 0.15% |
| Net Debt / EBIDTA | -582.37% |
| Price To Book | 5.06 |
| Price Earnings Ratio | 85.57 |
| Price To FCF | 77.31 |
| Price To sales | 18.59 |
| EV / EBITDA | 64.32 |
News
- Jan -24 - Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock?
- Jan -14 - Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
- Dec -27 - Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy
- Dec -19 - KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
- Dec -18 - Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
- Dec -13 - KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
- Dec -09 - Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
- Dec -04 - Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?
- Nov -27 - Krystal Biotech to Present at Upcoming Investor Conferences
- Nov -06 - Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
- Nov -05 - Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
- Nov -04 - Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript
- Nov -04 - Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
- Oct -28 - Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
- Oct -28 - Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
- Oct -18 - All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy
- Oct -14 - Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
- Sep -13 - Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
- Sep -06 - Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Aug -30 - Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceuticals
Expected Growth : 25.4 %
What the company do ?
Krystal Biotech, Inc. develops and commercializes pharmaceuticals, including gene therapies, to treat rare and serious diseases, leveraging its proprietary gene editing platform.
Why we expect these perspectives ?
Krystal Biotech's gene editing platform and pipeline of rare disease treatments drive growth, with increasing adoption of gene therapies and a growing demand for orphan drugs.
Krystal Biotech, Inc. Products
| Product Range | What is it ? |
|---|---|
| BEREGOVIRAGENE BEROVEC | A gene therapy candidate for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and debilitating genetic disorder that causes skin blisters and wounds. |
| KB103 | A topical gene therapy candidate for the treatment of dystrophic epidermolysis bullosa (DEB), designed to provide a convenient and pain-free treatment option. |
| KB105 | A gene therapy candidate for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis (ARCI), a rare genetic disorder that causes dry, scaly skin. |
| KB407 | A gene therapy candidate for the treatment of cystic fibrosis, a genetic disorder that affects the respiratory, digestive, and reproductive systems. |
Krystal Biotech, Inc.'s Porter Forces
Threat Of Substitutes
Krystal Biotech's gene therapy products are highly specialized and have limited substitutes, reducing the threat of substitutes.
Bargaining Power Of Customers
Krystal Biotech's customers are primarily hospitals and healthcare providers, who have limited bargaining power due to the company's unique products and limited competition.
Bargaining Power Of Suppliers
Krystal Biotech relies on a few key suppliers for raw materials and equipment, giving them some bargaining power, but the company's strong relationships and contracts mitigate this risk.
Threat Of New Entrants
The gene therapy industry has high barriers to entry, including significant R&D investments and regulatory hurdles, making it difficult for new entrants to compete with Krystal Biotech.
Intensity Of Rivalry
The gene therapy industry is highly competitive, with several established players and new entrants vying for market share, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.03% |
| Debt Cost | 4.24% |
| Equity Weight | 98.97% |
| Equity Cost | 8.18% |
| WACC | 8.14% |
| Leverage | 1.04% |
Krystal Biotech, Inc. : Quality Control
Krystal Biotech, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| SRPT | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It … |
| BPMC | Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment … |
| RNA | Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The … |
| ALNY | Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, … |
| BBIO | BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Avidity Biosciences
A-Score
1-Year Total Return ->
🥈
Alnylam Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Blueprint Medicines
A-Score
1-Year Total Return ->
4
Sarepta Therapeutics
A-Score
1-Year Total Return ->
5
Krystal Biotech
A-Score
1-Year Total Return ->
6
